Related Experiment Video
Updated: Jun 19, 2026

Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis
Published on: January 21, 2020
Paclitaxel-eluting stents
John Cosgrave1, Simon Corbett, Rade Babic
1EMO Centro Cuore Columbus & San Raffaele Hospital, Milan, Italy.
Abstract:
Percutaneous coronary intervention and stent implantation is rapidly becoming the most commonly used form of revascularization. The long term results of this procedure are limited by restenosis which is a phenomenon predominantly caused by proliferation of smooth muscle cells. Many devices and pharmaceutical agents have been unsuccessful in preventing this problem. Paclitaxel is an antiproliferative drug that has been extensively studied for the prevention of restenosis. This article will review the trial results of the currently available stent platforms and discuss some of the ongoing studies and future directions for the development of new paclitaxel-eluting stents.
Related Concept Videos
Drugs that Stabilize Microtubules
Peripheral Artery Disease III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

